TY  - JOUR
A1  - Schoffer, Olaf
A1  - Schülein, Stefanie
A1  - Arand, Gerlinde
A1  - Arnholdt, Hans
A1  - Baaske, Dieter
A1  - Bargou, Ralf C.
A1  - Becker, Nikolaus
A1  - Beckmann, Matthias W.
A1  - Bodack, Yves
A1  - Böhme, Beatrix
A1  - Bozkurt, Tayfun
A1  - Breitsprecher, Regine
A1  - Buchali, Andre
A1  - Burger, Elke
A1  - Burger, Ulrike
A1  - Dommisch, Klaus
A1  - Elsner, Gudrun
A1  - Fernschild, Karin
A1  - Flintzer, Ulrike
A1  - Funke, Uwe
A1  - Gerken, Michael
A1  - Göbel, Hubert
A1  - Grobe, Norbert
A1  - Gumpp, Vera
A1  - Heinzerling, Lucie
A1  - Kempfer, Lana Raffaela
A1  - Kiani, Alexander
A1  - Klinkhammer-Schalke, Monika
A1  - Klöcking, Sabine
A1  - Kreibich, Ute
A1  - Knabner, Katrin
A1  - Kuhn, Peter
A1  - Lutze, Stine
A1  - Mäder, Uwe
A1  - Maisel, Tanja
A1  - Maschke, Jan
A1  - Middeke, Martin
A1  - Neubauer, Andreas
A1  - Niedostatek, Antje
A1  - Opazo-Saez, Anabelle
A1  - Peters, Christoph
A1  - Schell, Beatrice
A1  - Schenkirsch, Gerhard
A1  - Schmalenberg, Harald
A1  - Schmidt, Peter
A1  - Schneider, Constanze
A1  - Schubotz, Birgit
A1  - Seide, Anika
A1  - Strecker, Paul
A1  - Taubenheim, Sabine
A1  - Wackes, Matthias
A1  - Weiß, Steffen
A1  - Welke, Claudia
A1  - Werner, Carmen
A1  - Wittekind, Christian
A1  - Wulff, Jörg
A1  - Zettl, Heike
A1  - Klug, Stefanie J.
T1  - Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011
JF  - BMC Cancer
N2  - Background

Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients.

Methods

Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival.

Results

The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%).

Conclusions

No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.
"
KW  - Malignant melanoma
KW  - TNM staging
KW  - Survival analysis
KW  - Skin cancer screening
KW  - Stage distribution
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164544
VL  - 16
IS  - 936
ER  - 
TY  - JOUR
A1  - Truongvan, Ngoc
A1  - Li, Shurong
A1  - Misra, Mohit
A1  - Kuhn, Monika
A1  - Schindelin, Hermann
T1  - Structures of UBA6 explain its dual specificity for ubiquitin and FAT10
JF  - Nature Communications
N2  - The covalent modification of target proteins with ubiquitin or ubiquitin-like modifiers is initiated by E1 activating enzymes, which typically transfer a single modifier onto cognate conjugating enzymes. UBA6 is an unusual E1 since it activates two highly distinct modifiers, ubiquitin and FAT10. Here, we report crystal structures of UBA6 in complex with either ATP or FAT10. In the UBA6-FAT10 complex, the C-terminal domain of FAT10 binds to where ubiquitin resides in the UBA1-ubiquitin complex, however, a switch element ensures the alternate recruitment of either modifier. Simultaneously, the N-terminal domain of FAT10 interacts with the 3-helix bundle of UBA6. Site-directed mutagenesis identifies residues permitting the selective activation of either ubiquitin or FAT10. These results pave the way for studies investigating the activation of either modifier by UBA6 in physiological and pathophysiological settings.
KW  - enzyme mechanisms
KW  - post-translational modifications
KW  - X-ray crystallography
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-301161
VL  - 13
ER  -